TrialInvestigational new drugs2015

Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.

Daniel P Petrylak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.